News > SII Seeks Authorisation for India’s First QHPV Vaccine Against Cervical Cancer
SII Seeks Authorisation for India’s First QHPV Vaccine Against Cervical Cancer
Dais Newsfeed | 09/06/2022 08:08 AM | Click to read full article
Serum Institute of India (SII) has applied to the country’s drug regulator seeking market authorisation to manufacture indigenously developed India’s first Quadrivalent Human Papillomavirus vaccine (qHPV) against cervical cancer.
SII said the vaccine CERVAVAC has demonstrated robust antibody response that is nearly 1000 times higher than the baseline against all targeted HPV types and in all dose and age groups.
